The Claim
In aged mice, intranasal administration of human induced pluripotent stem cell-derived neural stem cell extracellular vesicles reduces the formation of disease-associated microglial clusters and decreases the percentage of microglia containing NLRP3-ASC inflammasome complexes.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In older mice, a treatment using tiny particles derived from stem cells, delivered through the nose, reduces specific inflammatory structures in brain immune cells that are linked to neurodegenerative conditions.
See the scientific wording
In aged mice, intranasal hiPSC-NSC-EVs reduce the formation of disease-associated microglial clusters and the percentage of microglia containing NLRP3-ASC inflammasome complexes, indicating suppression of chronic neuroinflammatory activation.
Tiny bubbles from stem cells, sprayed into the nose, travel to the brain and get absorbed by immune cells there. These bubbles carry a special molecule that blocks the production of a key protein needed to turn on a dangerous inflammatory switch inside the immune cells. Without this switch, the immune cells don't release harmful chemicals, stop clustering abnormally, and return to a calmer state.
What the research says
1 studyIn older mice, tiny bubbles released by stem cells, when sprayed into the nose, helped calm down overactive brain immune cells and stopped them from turning on their inflammatory machinery. This means the treatment reduced harmful brain inflammation.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.